Evidence map›Paper›PMID 31783139›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2020

MXD3 antisense oligonucleotide with superparamagnetic iron oxide nanoparticles: A new targeted approach for neuroblastoma.

Sakiko Yoshida, Connie Duong, Michael Oestergaard, Michael Fazio, Cathy Chen, Rachael Peralta, Shuling Guo, Punit P Seth, Yueju Li, Laurel Beckett and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Histochemistry for Molecular Imaging in Nanomedicine.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Nanocarriers for Delivery of Oligonucleotides to the CNS.International journal of molecular sciences · 2022
    Review
  10. Review
  11. Article
  12. Noncoding RNA therapeutics for substance use disorder.Advances in drug and alcohol research · 2022
    Article
  13. Article
  14. Article
  15. Emerging therapeutic targets for neuroblastoma.Expert opinion on therapeutic targets · 2020
    Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Sakiko YoshidaDepartment of Pediatrics, University of California, Davis, Sacramento, CA, USA; Department of Pediatrics, Niigata University, Japan.
Connie DuongDepartment of Pediatrics, University of California, Davis, Sacramento, CA, USA.
Michael OestergaardIonis Pharmaceuticals, Carlsbad, CA, USA.
Michael FazioIonis Pharmaceuticals, Carlsbad, CA, USA.
Cathy ChenDepartment of Pediatrics, University of California, Davis, Sacramento, CA, USA.
Rachael PeraltaIonis Pharmaceuticals, Carlsbad, CA, USA.
Shuling GuoIonis Pharmaceuticals, Carlsbad, CA, USA.
Punit P SethIonis Pharmaceuticals, Carlsbad, CA, USA.
Yueju LiDepartment of Public Health Sciences, University of California, Davis, Sacramento, CA, USA.
Laurel BeckettDepartment of Public Health Sciences, University of California, Davis, Sacramento, CA, USA.
Nitin NitinDepartments of Food Science & Technology and Biological & Agricultural Engineering, University of California, Davis, Davis, CA, USA.
Noriko SatakeDepartment of Pediatrics, University of California, Davis, Sacramento, CA, USA. Electronic address: nsatake@ucdavis.edu.
University of California, Davis · USIonis Pharmaceuticals (United States) · USNiigata University · JP

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
UC Davis Clinical and Translational Science CenterUL1TR000002 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2012 to 2015
$12.2M
NCATS NIH HHS UL1 TR000002NCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

Neuroblastoma (NB) is the most common extracranial solid tumor in children. The outcomes for aggressive forms of NB remain poor. The aim of this study was to develop a new molecular-targeted therapy for NB using an antisense oligonucleotide (ASO) and superparamagnetic iron oxide (SPIO) nanoparticles (NPs), as a delivery vehicle, targeting the transcription regulator MAX dimerization protein 3 (MXD3). We previously discovered that MXD3 was highly expressed in high-risk NB, acting as an anti-apoptotic factor; therefore, it can be a good therapeutic target. In this study, we developed two ASO-NP complexes using electrostatic conjugation to polyethylenimine-coated SPIO NPs and chemical conjugation to amphiphilic polymers on amine-functionalized SPIO NPs. Both ASO-NP complexes demonstrated MXD3 knockdown, which resulted in apoptosis in NB cells. ASO chemically-conjugated NP complexes have the potential to be used in the clinic as they showed great efficacy with minimum NP-associated cytotoxicity.

Indexed as

ApoptosisCell Line, TumorFerric CompoundsGene SilencingHumansImmunoblottingImmunohistochemistryMagnetite NanoparticlesMetal NanoparticlesNeuroblastomaOligonucleotides, AntisenseRepressor ProteinsStatic ElectricityFerric Compoundsferric oxideMagnetite NanoparticlesMXD3 protein, humanOligonucleotides, AntisenseRepressor ProteinsAntisense oligonucleotideGene silencingNanoparticleNeuroblastomaTargeted therapy

Identifiers

PMID31783139
PMCPMC7515558
OpenAlexW2991326439

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.